Domača stranBNTX • NASDAQ
add
BioNTech
89,27 $
Po zaprtju:(0,59 %)+0,53
89,80 $
Konec trgovanja: 20. mar., 19:18:26 GMT -4 · USD · NASDAQ · Izjava
Prejšnji trg. dan.
89,31 $
Dnevni razpon
87,16 $ - 89,62 $
Letni razpon
79,52 $ - 123,98 $
Tržna kapitalizacija
23,51 mrd. USD
Povprečni obseg
1,33 mio.
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
NASDAQ
V novicah
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (EUR) | dec. 2025info | Sprememba L/L |
|---|---|---|
Prihodek | 907,40 mio. | −23,75 % |
Stroški poslovanja | 907,20 mio. | 15,13 % |
Čisti dohodek | −305,00 mio. | −217,53 % |
Čista dobičkovnost prihodkov | −33,61 | −254,10 % |
Earnings per share | −0,33 | −130,56 % |
EBITDA | −266,95 mio. | −195,92 % |
Efektivna davčna stopnja | −34,12 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (EUR) | dec. 2025info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 13,74 mrd. | −13,28 % |
Skupna sredstva | 21,99 mrd. | −2,40 % |
Skupne obveznosti | 2,76 mrd. | −11,36 % |
Celoten lastniški kapital | 19,22 mrd. | — |
Shares outstanding | 239,97 mio. | — |
Razmerje P/B | 1,17 | — |
Donosnost sredstev | −3,49 % | — |
Donosnost kapitala | −3,96 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (EUR) | dec. 2025info | Sprememba L/L |
|---|---|---|
Čisti dohodek | −305,00 mio. | −217,53 % |
Denar iz dejavnosti | 309,50 mio. | 166,80 % |
Denar iz naložb | −2,73 mrd. | −549,25 % |
Denar iz financiranja | −14,30 mio. | −95,89 % |
Neto sprememba denarnih sredstev | −2,42 mrd. | −1.860,74 % |
Prost denarni tok | −1,44 mrd. | −27,63 % |
Vizitka
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
Generalni direktor
Datum ustanovitve
2008
Spletno mesto
Zaposleni
7.807
